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Sarcopenia Screening by Registered Dietitian Nutritionists (RDNs)  




Sarcopenia is a disease of muscle wasting primarily seen in older adults. Although this term was 
first coined over three decades ago, there is a lack of consensus on a definition, screening 
criteria, and treatment protocol for sarcopenia. The primary purpose of this study is to determine 
whether registered dietitian nutritionists (RDNs) in the United States (U.S.) screen for 
sarcopenia. Study participants were recruited through a randomized email list and included 
RDNs throughout the U.S. Respondents completed a survey questioning knowledge of 
sarcopenia, screening tools and company protocols in place, and the need and desire for 
sarcopenia education. Data revealed a lack of pre-existing protocols in place, a dissonance of 
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Chapter 1. Introduction 
Sarcopenia was first defined in 1989 by Irwin Rosenberg as the age-related loss of 
muscle mass and function from the Greek roots “sarx” for flesh and “penia” for loss (Rosenberg, 
1989).  Several updated definitions have been proposed since the introduction of the term, but 
there has yet to be an established global or even national definition. Without specific guidelines 
for diagnosis and treatment of sarcopenia, statistics have been estimated but not verified.   
In 2014, the European Working Group on Sarcopenia in Older People (EWGSOP) and 
the International Working Group on Sarcopenia (IWGS) conducted a systematic review that 
found the prevalence of sarcopenia to be between 1-29% for older, free-living people, 14-33% 
for those in long-term care institutions, and 10% for those in acute care settings (A. Cruz-Jentoft 
et al., 2014). These wide ranges are just one example of the variation in definitions, diagnoses, 
and treatment of sarcopenia. More recently, a systematic review conducted in 2017 found that 
10% of men and 10% of women amongst over 58,000 individuals over the age of 60 had 
sarcopenia (Shafiee et al., 2017). This study included several established definitions including 
those set by the EWGSOP, the IWGS and the AWGS (Asian Working Group on Sarcopenia). 
Similarly, Bonetto and Bonewald (2019) estimated that the prevalence of sarcopenia would be 
20% of the world’s population by the year 2050 and one-third of the population by 2150. 
However, a second review published in 2019 found that 43% of men and 46% of women had 
sarcopenia (Shen et al., 2019). The criteria included 16 studies, over 3,500 participants, and 
included only nursing home residents. With only the EWGSOP definition as the determinant for 
this review, there is a higher level of incidence when compared to the previous systematic 
review. Additionally, there was a statistically significant difference between the prevalence of 
malnutrition independent of sarcopenia prevalence found in this review. 
12 
 
A study published in 2019 found that the annual cost of sarcopenia-related 
hospitalizations in the U.S. is estimated to be $40.4 billion U.S. dollars each year (Goates et al., 
2019). In comparison, several of the same authors of this 2019 study previously investigated the 
healthcare costs related to disease-related malnutrition. Although this study published in 2016 
looked at only eight diseases (stroke, COPD, CHF, breast cancer, dementia, musculoskeletal 
disorders, depression, and colorectal cancer) that were associated with malnutrition and did not 
include acute disease-related or environmental malnutrition, the findings were still conclusive. It 
was estimated that this set of disease-associated malnutrition prevalence costs approximately 
$15.5 billion U.S. dollars (Goates et al., 2016). It is understood that these estimates cannot be 
directly compared. However, the research and understanding of malnutrition has a further reach 
than that of sarcopenia now. By extension of this logic, it is possible that the annual healthcare 
cost of sarcopenia could potentially be decreased by further research, understanding, and defined 
criteria of sarcopenia. 
Similar to related diseases and terms including malnutrition, cachexia, and frailty, there 
exists a need for universally agreed upon screening, assessment, and treatment protocols for 
sarcopenia. The purpose of this study is trifold and includes determining whether or not 
registered dietitian nutritionists (RDNs) in the United States (U.S.) screen for sarcopenia; 
identifying which tools, if any, are used to screen and identify patients at risk for sarcopenia and 
any standard protocols in place; and identifying if there is a need and/or desire for education on 





Chapter 2. Review of the Literature 
Sarcopenia Definition and Background 
As stated above, sarcopenia was first defined in 1989 by Irwin Rosenberg as the age-
related loss of muscle mass and function from the Greek roots “sarx” for flesh and “penia” for 
loss (Rosenberg, 1989). The European Working Group on Sarcopenia in Older People 
(EWGSOP2) convened in 2018—nearly a decade after the first meeting—to determine a new 
and improved definition for sarcopenia based on the evidence available. The EWGSOP2 
determined that “sarcopenia is a muscle disease (muscle failure) rooted in adverse muscle 
changes that accrue across a lifetime”; however, it is more common in older adults but can occur 
earlier in life (Cruz-Jentoft et al., 2018). The EWGSOP2 also discussed inclusion criteria for 
sarcopenic diagnosis as shown in Table 1 below. 
Table 1 
Proposed Sarcopenia Diagnosis Criteria 
Probable sarcopenia is identified by Criterion 1. 
Diagnosis is confirmed by additional documentation of Criterion 2. 
If Criteria 1, 2 and 3 are all met, sarcopenia is considered severe. 
(1) Low muscle strength 
(2) Low muscle quantity or quality 
(3) Low physical performance 
Table 1. Proposed Sarcopenia Diagnosis Criteria 
Note. Retrieved from "Sarcopenia: revised European consensus on definition and diagnosis" by 
A. J. Cruz-Jentoft, G. Bahat, J. Bauer, et al., 2018, Age and Ageing, 48, p. 16-31. Copyright 2018 
by the Authors. 
 
Sarcopenia is now a billable diagnosis for reimbursement in some countries as of 2016 
(Cao & Morley, 2016). Several updated definitions have been proposed, but there has yet to be a 
definitive and global definition established (Lee et al., 2013; Morley et al., 2001; Shen et al., 
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2019). Aside from EWGSOP, other organizations throughout the world have proposed 
definitions of sarcopenia including the following: 
• The International Working Group on Sarcopenia (IWGS) published in 2011 that: 
Sarcopenia is the age-associated loss of skeletal muscle mass and function. 
Sarcopenia is a complex syndrome that is associated with muscle mass loss alone 
or in conjunction with increased fat mass. The causes of sarcopenia are multi-
factorial and can include disuse, changing endocrine function, chronic diseases, 
inflammation, insulin resistance, and nutritional deficiencies. While cachexia may 
be a component of sarcopenia, the two conditions are not the same (Fielding et al., 
2011).  
• The Asian Working Group for Sarcopenia (AWGS) has agreed that sarcopenia should be 
described as low muscle mass, low muscle strength, and low physical performance; in 
comparison to EWGSOP, AWGS recommends measuring both muscle strength and 
physical performance as well as established lower cutoff measurements for the Asian 
populations compared to non-Asian populations (Chen et al., 2014). 
• The European Society of Clinical Nutrition and Metabolism (ESCNM), the International 
Sarcopenia Initiative (ISI), and the Foundation for the National Institutes of Health 
(FNIH) have stated their affirmations in the original definition set forth by the EWGSOP 
(Cederholm et al., 2017; Cruz-Jentoft et al., 2014; S. A. Studenski et al., 2014).   
Muscle Mass, Strength, and Loss 
Many studies have shown that muscle mass and strength decline as an individual ages 
(Delmonico et al., 2009; Distefano & Goodpaster, 2018; Koster et al., 2011; Lexell et al., 1988). 
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Additionally, it is widely agreed upon that once individuals reach the age of fifty, muscle mass 
declines at a rate of 1-2% per year and muscle strength declines at a rate of 1.5-3% per year 
(Lang et al., 2010). It has also been found that muscle strength declines faster than muscle mass 
as a rate of two to five times (Koster et al., 2011). Although determinants for this age-induced 
loss of muscle mass and strength vary, there are several modifiable factors in which individuals 
can slow the rates of decline.  
These modifiable factors include obesity, obesity-related conditions, and physical 
inactivity, among others (Distefano & Goodpaster, 2018). Obesity coupled with loss of muscle 
mass and function has been deemed sarcopenic obesity. This seemingly oxymoron has been 
proven in that increased adipose tissue negatively affects muscle function as well as decreases 
handgrip strength, to be discussed in following sections (Koster et al., 2011; Stenholm et al., 
2008). As muscle protein synthesis declines with aging, resistance exercise has been shown to 
have similar effects in both older and younger cohorts (Schulte & Yarasheski, 2001). 
Furthermore, as oxidative stress increases in older adults, mitochondrial function decreases in 
part due to lack of physical activity (Safdar et al., 2010). 
Sarcopenia Development 
Development and progression of sarcopenia is largely associated with age and a decrease 
in skeletal muscle mass and strength if it is classified as primary sarcopenia. Secondary 
sarcopenia is considered when there are external factors aside from aging such as nutrition, 
activity, or disease that act as the cause (A. J. Cruz-Jentoft et al., 2018; Meron & Akuthota, 
2018). In terms of primary sarcopenia, reduced physical activity and increased amount of time 
spent in bed can in part explain the increase in sarcopenia prevalence by way of decline in 
skeletal muscle mass (Bonetto & Bonewald, 2019). In addition, both acute and chronic 
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sarcopenia exist dependent on the length of time before sarcopenia is expressed which has been 
established by the EWGSOP2. Acute sarcopenia develops within 6 months and is often triggered 
by hospitalization or a high-level stressor event. On the other hand, chronic sarcopenia is that 
which has lasted longer than 6 months and is often related to aging, chronic disease, or 
progressive diseases (A. J. Cruz-Jentoft et al., 2018).   
 When reviewing sarcopenia, other related terms of interest include: 
• Sarcopenic obesity was first loosely defined in 1996 as “reduced lean mass with 
excess fat as a percentage of body weight” (Heber et al., 1996). More recently and 
most notably, sarcopenic obesity is when “loss of muscle and gain in fat occur 
together… it may be that the gain in fat and the loss of muscle reinforce each 
other, and act synergistically” (Roubenoff, 2001). The latter has been noted and 
has been the basis in several more recent studies as well (Schrager et al., 2007; 
Scott et al., 2015; Stenholm et al., 2008). 
• Dynapenic obesity is relative to muscle strength with excess body fat in 
comparison to sarcopenic obesity that is relative to muscle mass with excess body 
fat (Scott et al., 2015). Dynapenic obesity has gained popularity due to its 
increased association in functional decline compared to sarcopenic obesity (Scott 
et al., 2014).  
• Frailty was originally defined in 2001 in a study looking at community-dwelling 
adults as “a clinical syndrome in which three or more of the following criteria 
were present: unintentional weight loss (10 lbs. in past year), self-reported 
exhaustion, weakness (grip strength), slow walking speed, and low physical 
activity” (Fried et al., 2001). However, it has more recently been observed in 
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terms of cognitive impairment in addition to the traditional physical impairment. 
This newer definition states that cognitive frailty is a “heterogeneous clinical 
manifestation characterized by the simultaneous presence of both physical frailty 
and cognitive impairment,” which also includes additional criteria (Kelaiditi et al., 
2013). 
• Malnutrition is overarchingly defined as “a state of nutrition in which a deficiency 
of energy, protein, and other nutrients causes adverse effects on the body’s size, 
composition, and function resulting in poorer clinical outcomes” (Stratton et al., 
2018).  
• Cachexia, similar to those discussed above, does not have an explicit definition. 
In 2008, clinicians and scientists met at the cachexia consensus conference to 
establish a definition for cachexia. The agreed upon definition of cachexia 
established was “a complex metabolic syndrome associated with underlying 
illness and characterized by loss of muscle with or without loss of fat mass” 
(Evans et al., 2008). 
Screening and Assessment of Sarcopenia 
Based on the number of working groups and organizations both discussed and not 
throughout this research, it is no surprise that there is not a definitive definition and screening 
protocol in place for sarcopenia. As stated above, there is no universally agreed upon definition 
for sarcopenia. Considering the variance amongst definitions, the same progression has been set 
for assessing those at risk for sarcopenia; there is also a lack of consensus for the screening and 
assessment of sarcopenia. A variety of tools, both validated and not, have been introduced for 
identifying those at risk of sarcopenia. These tools can be found in research and/or clinical 
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settings, have benefits and drawbacks, and some have more realistic applications than others. 
Following are descriptions of validated tests used in screening and diagnosing sarcopenia. 
SARC-F 
The SARC-F (strength, assistance in walking, rise from a chair, climb stairs, and falls) 
tool is one of the most common tools used in both research and clinical settings due to its high 
level of specificity and short administration time. Each component includes a question that is 
self-reported by the participant and is given a score of 0, 1, or 2. A total score of 4 or higher is 
indicative of a sarcopenia diagnosis (Li et al., 2019). The strength component questions how 
much difficulty the individual has in lifting and carrying 10 pounds with the scoring ranging 
from 0 (no difficulty), 1 (some difficulty), or 2 (a lot of difficulty or unable). The assistance in 
walking component questions how much difficulty the individual has in walking across a room 
with the scoring ranging from 0 (no difficulty), 1 (some difficulty), or 2 (a lot of difficulty, use of 
aids or unable). The rise from a chair component questions how much difficulty the individual 
has in transferring from a chair or a bed with the scoring ranging from 0 (no difficulty), 1 (some 
difficulty), or 2 (a lot of difficulty or unable without assistance). The climbing stairs component 
questions how much difficulty the individual has in climbing a flight of 10 stairs with the scoring 
ranging from 0 (no difficulty), 1 (some difficulty), or 2 (a lot of difficulty or unable). Finally, the 
falls component questions how many times the individual has fallen in the past year with the 
scoring ranging from 0 (no falls), 1 (1-3 falls), or 2 (4 or more falls) (Malmstrom & Morley, 
2013). The SARC-F has been validated since its development in 2013 and has been found 
suitable for use in community-dwelling older adults (Malmstrom & Morley, 2013). A visual 




Ishii’s Score was developed by a group of health professionals in Japan in 2014 (Ishii et 
al., 2014). The score is calculated by acquiring age, grip strength, and calf circumference and 
inputting this data into a formula. For men, the formula [0.62 X (age – 64) – 3.09 X (HS – 50) – 
4.64 X (CC – 42)] is used where CC is calf circumference and HS is handgrip strength with the 
cut-off point ≥105 (Ishii et al., 2014). For women, the formula [0.80 X (age – 64) – 5.09 X (HS – 
34) – 3.28 X (CC – 42)] is used where CC is calf circumference and HS is handgrip strength with 
the cut-off point ≥120 (Ishii et al., 2014). Although Ishii’s Score has been validated, it has only 
been done so with Japanese participants (Tang et al., 2018). More recently, a group of public 
health professionals based in Belgium recommended a cutoff range of 111.1 to 128.5 for both 
men and women to better decipher amongst individuals at risk for sarcopenia (Locquet et al., 
2018). This group also found that Ishii’s Score demonstrated the best sensitivity and negative 
predictive value (NPV) as well as the highest area under the curve (AUC) when compared to 
four other sarcopenia screening tools (Locquet et al., 2018). Although Ishii’s Score has only been 
validated for Japanese older adults, it has been validated to determine the 3-year mortality rate in 
Chinese older adults (Tang et al., 2018). Similar to the SARC-F, Ishii’s Score was tested and 
validated for use in community-dwelling older adults regardless of ethnicity and demographics 
(Morandi et al., 2015). See Appendix B for the published version of Ishii’s Score. 
MSRA Questionnaire  
The MSRA (Mini Sarcopenia Risk Assessment) questionnaire was developed in 2017 in 
Italy to serve as a prescreening tool for sarcopenia in community-dwelling older adults (Rossi et 
al., 2017). The MSRA-7 includes 7 questions comprising of age, hospitalizations, physical 
activity level, weight loss, number of meals consumed per day, dairy consumption, and protein 
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consumption with scores of 0, 5, or 10 (Rossi et al., 2017). The MSRA-5 is comprised of the 
same questions omitting the dairy and protein consumption questions with scores of 0, 5, 10, or 
15. The cutoff score for both versions of the MSRA is 30 points with individuals having a score 
below 30 points being four times more likely to develop sarcopenia than those with a score 
above 30 points (Rossi et al., 2017). High sensitivity of the MSRA questionnaire lends it to be a 
good choice for a first-line of defense while the higher specificity of the SARC-F tool makes it 
out to be a better choice for a second-line defense (Yang et al., 2019). Similar to Ishii’s Score, 
MSRA needs to be tested amongst populations other than Asian or Italian descent, respectively, 
to determine a higher accuracy (Yang et al., 2019). Similar to SARC-F and Ishii’s Score, MSRA 
determines sarcopenia screening based on the EWGSOP definition (A. J. Cruz-Jentoft et al., 
2018; Ishii et al., 2014; Malmstrom & Morley, 2013; Rossi et al., 2017). See Appendix C for the 
published versions of the MSRA questionnaire. 
SarQoL Questionnaire 
The SarQoL (Sarcopenia Quality of Life) was established in 2015 (Beaudart et al., 2015) 
and validated in English in 2017 (Beaudart, Biver, et al., 2017) as a disease-specific quality of 
life assessment for persons with sarcopenia. Experts in the field at the time believed that an 
assessment on quality of life specific to sarcopenia was necessary for patient safety and 
treatment. The questionnaire was originally written in French but is now available in 31 other 
languages, including English, with another six translations in progress. However, only five of the 
translated versions have been validated. After determining the domains and questions to be 
answered on behalf of individuals with sarcopenia, the original team decided upon 55 items that 
were addressed in 22 questions. Although it was originally designed for individuals 65 years of 
age and older in community-dwelling settings, it is widely used for a variety of ages and living 
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situations. The questionnaire takes about 10 minutes to complete for a total possible score of 100 
points (Beaudart, Reginster, et al., 2017). See Appendix D for the published version of the 
SarQoL. 
Bioelectrical Impedance Analysis  
Bioelectrical impedance analysis (BIA) indirectly measures the skeletal muscle mass by 
way of low-grade electrical impulses sent through the body (A. J. Cruz-Jentoft et al., 2018). 
Although dual-energy x-ray absorptiometry (DXA) imaging is more accurate and deemed an 
appropriate tool for determining skeletal muscle mass, it is more costly and harder to gain access 
to than BIA (Dent et al., 2018; Gonzalez & Heymsfield, 2017). BIA is also endorsed as a 
secondary means of obtaining skeletal muscle mass by the EWGSOP, AWGS, and the 
International Consensus for Cancer Cachexia (ICCC), but current literature does not support the 
use of BIA for the diagnosis of sarcopenia (Dent et al., 2018; Gonzalez & Heymsfield, 2017). 
However, the use of non-imaging techniques leave room for  greater variety of error and lack of 
accuracy (Boutin et al., 2015).  
Other Screening Tools 
 Convened in 2016, the Global Leadership Initiative on Malnutrition (GLIM) received 
feedback from members of several of the world’s prominent clinical nutrition organizations and 
societies in order to define a global diagnostic criterion for malnutrition (Cederholm et al., 2019). 
Leaders of GLIM consist of members from American Society for Parenteral and Enteral 
Nutrition (ASPEN), European Society for Clinical Nutrition and Metabolism (ESPEN), Latin 
American Federation of Nutritional Therapy, Clinical Nutrition and Metabolism (FELANPE), 
Parenteral and Enteral Society of Asia (PENSA), as well as additional representation from other 
organizations to gain insight from all around the world. The prominence of this research and 
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proposed diagnostic criteria for malnutrition is essential for the progression of global diagnostic 
benchmarks for sarcopenia. Also discussed throughout the GLIM committee meetings were the 
relationships between malnutrition, cachexia, sarcopenia, and frailty. The GLIM consensus 
reported that the proposed diagnostic criteria be used in conjunction with preexisting criteria for 
sarcopenia, frailty, and cachexia (Cederholm et al., 2019). Based on the GLIM proposed global 
malnutrition diagnosis criteria, previously studied correlations between frailty with gait speed, 
cachexia with handgrip strength, and sarcopenia with assessment of food intake can each be 
found to coexist with one or more of the described counterparts. This stated, an assessment of 
gait speed, handgrip strength, and assessment of food intake is integral in understanding 
sarcopenia screening, diagnostics, and treatments. 
Gait Speed 
Gait speed, often referred to as the “6th vital sign”, has been utilized by physical 
therapists, occupational therapists, and neurologists alike (Middleton et al., 2015). Gait speed, or 
walking speed, requires energy, control of basic movements, support, and involves multiple 
organ systems in the body (Studenski et al., 2011). It has been concluded that a decline in gait 
speed has a correlation with disabilities, cognitive impairment, fall risk, and mortality (Van Kan 
et al., 2009). With specificity to this research, it has been established by the International 
Academy on Nutrition and Aging (IANA) that there is sufficient evidence available to determine 
that gait speed is a strong predictive indicator of undesirable outcomes in community-dwelling 
older adults (Van Kan et al., 2009). 
Handgrip Strength 
Skeletal muscle mass and muscle strength, while related, are independent of one another. 
It has been shown that muscle strength declines at a much higher rate (2-4 times) than muscle 
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mass and can be indicative of adverse outcomes (Wall et al., 2013). The relationship between 
handgrip strength and these adverse health effects is not considered new information. A study 
conducted in 1984 found that patients with lower handgrip strength scores had an increased 
occurrence of  postoperative complications (Davies et al., 1984). Handgrip strength has also been 
shown to be connected to mortality, morbidity, and frailty (Cooper et al., 2011; Syddall et al., 
2003). In terms of screening for sarcopenia, handgrip strength (grip strength) was not included in 
the position of the International Clinical Practice Guidelines for Sarcopenia (ICFSR) for valid 
reasons as discussed in those guidelines (Dent et al., 2018). However, the ICFSR recommends 
the use of grip strength—as well as gait speed—as diagnostic criteria for sarcopenia (Dent et al., 
2018).  
Assessment of Food Intake 
Unintentional weight loss can be an indicator for loss of muscle mass and, ultimately, 
both malnutrition and sarcopenia. In terms of malnutrition, conducting a 24-hour food recall or 
short diet history is cumbersome and tedious for both the interviewer and interviewee. Food 
frequency questionnaires (FFQ), however, are less invasive on time, skills, and the respondents’ 
responsibility overall (Steinemann et al., 2017). Understanding the relationships that exist 
between malnutrition and sarcopenia—as well as cachexia—and the tools used to screen for and 
diagnose them, is critical for identifying future treatment options. Although many tools are 
available, there is no single, validated tool available to screen for more than one of these 
conditions concurrently (Miller et al., 2018). With each condition being a possible outcome to 
nutritional inadequacies or imbalances, it is vital to identify or develop tools that can overlap, as 
well. The Academy of Nutrition and Dietetics (AND) published an updated position paper in 
24 
 
2019 stating that the malnutrition screening tool (MST) should be used to screen for 
malnutrition, or undernutrition, in adults (Skipper et al., 2019).   
Sarcopenia Treatment 
 Although treatment options for sarcopenia are not established, there are various 
treatments that have been studied including physical activity, dietary modifications, supplement 
use, and even hormone replacement therapies.  
Physical Activity 
 A prominent randomized controlled trial conducted in 2014, the LIFE (Lifestyle 
Interventions and Independence for Elders) study followed over 1,600 individuals over the span 
of two and a half years (Pahor et al., 2014). This pioneer study observed the effects of either a 
structured physical activity program or health education program on mobility disability. The 
physical activity group members were instructed to participate in various individualized 
exercises including walking, resistance exercises, and strength training while members of the 
health education group were instructed to attend workshops focused on “successful ageing” and 
also included minor stretching exercises (Pahor et al., 2014). The LIFE study found that 
compared to baseline 400 meter walking distances and times, participants in the physical 
exercise cohort experienced lower major and persistent mobility deficits with 30.1% (n=246 of 
818) and 14.7% (n=120 of 818) when compared to the health education cohort’s major and 
persistent mobility deficits with 35.5% (n=290 of 817) and 19.8% (n=162 of 817), respectively 
(Pahor et al., 2014). 
Changes to Diet and Supplements 
 Although the evidence is not as strong for nutritional interventions without exercise as for 
physical exercise alone, there remains a strong interest in research related to nutrition 
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interventions to treat sarcopenia. Of note, one review published in 2018 discussed the mounting 
evidence of the importance of adequate protein, vitamin D, antioxidant and long-chain 
polyunsaturated fatty acids (LCPUFA) in healthy ageing (Robinson et al., 2018). The Working 
Group, comprised of members of ESCEO (European Society for Clinical and Economic Aspects 
of Osteoporosis, Osteoarthritis, and Musculoskeletal Diseases), discussed the importance of 
these nutrients, the research strengths and limitations, and further research needs in order to 
determine specific nutrition interventions for the treatment of sarcopenia. 
Sarcopenia in Practice Settings 
With the lack of global consensus on the screening, assessment, treatment, and even 
explicit definition of sarcopenia, there is no one healthcare profession that has been shown to 
explicitly inquire about sarcopenia in practice today. Based on the primary sarcopenia aspects 
including muscle mass and strength, nutrition intake, and related diseases such as malnutrition, 
cachexia and frailty, there are several professions that would be most abreast of sarcopenia 
diagnosis and treatment. Regarding muscle mass and strength with and without relation to frailty, 
physical therapists and/or occupational therapists seem to coincide best with this aspect. 
Nutrition corresponds best with registered dietitian nutritionists who work closely with physical 
therapists and occupational therapists regarding patient status and outcomes. With a lack of 
separate or shared responsibilities defined for each of these professions—as well as other 
healthcare professionals—it begs the question of who currently screens, assesses, treats, and 
monitors those with sarcopenia? In addition, what profession more closely coincides with these 
stated responsibilities and should conduct proper sarcopenia treatment? The aim of the proposed 
research questions focuses on the registered dietitian nutritionists’ current role and future of 
sarcopenia screening, assessment, and treatment.  
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The following three research questions were investigated regarding the responses 
obtained from the formulated survey: 
RQ1: Do registered dietitian nutritionists routinely screen and identify patients at risk for 
sarcopenia? 
RQ2: Are there any screening tools which are commonly used to screen and identify patients at 
risk for sarcopenia, and are there any protocols in place? 
RQ3: Is there a need and/or a desire for education for registered dietitian nutritionists on what 




Chapter 3. Methods 
Survey Design 
 Data was collected using a 29-question survey comprised of 9 demographic questions and 
20 sarcopenia-related questions. Throughout the survey, the option was given not to answer 
specific questions should the participant so choose. In addition, not all 29 questions were 
answered by all participants dependent on answers selected for previous questions. The survey 
was developed by the primary investigator and feedback was received by the thesis committee 
comprised of two registered dietitian nutritionists (RDN) and one physical therapist (PT). The 
survey took approximately 5 minutes to complete. See Appendix E for the complete survey. 
Study Population 
 The study population included 210 RDNs in the U.S. Study participants met the 
following inclusion criteria: (1) over the age of 18 years of age, (2) registered dietitian 
nutritionist in the United States. Exclusion criteria included: (1) under the age of 18 years of age, 
(2) not a registered dietitian nutritionist in the United States. 
Survey Implementation 
The Commission on Dietetic Registration (CDR) is the credentialing agency for the 
Academy of Nutrition and Dietetics (AND) for RDNs in the U.S. After filing an application, 
CDR provided a random list of 5,000 email addresses of RDNs throughout the U.S. In November 
2020, the survey was distributed to all 5,000 RDNs via an email with a Qualtrics survey link.  
Respondents were notified of potential risks and benefits of the study. This study was initially 
approved by the East Tennessee State University (ETSU) Institutional Review Board (IRB) on 
September 14, 2020. Minor revisions were made to the survey and revised approval by ETSU 
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IRB was received on October 29, 2020. The survey was closed for participation on December 5, 
2020.  
Data Collection, Coding, and Cleaning 
After the closure of the survey, data were downloaded from Qualtrics as an Excel file, 
then coded and imported into IBM Statistical Package for Social Sciences (SPSS), version 27. 
Variables for testing were based upon the study’s questions and interest in further discoveries of 
these groupings. The chosen variables for analysis are provided in Appendix F. Surveys from 
participants that were incomplete were coded but were disregarded in the data analysis process. 
Data Analysis 
 Data analysis was completed using SPSS, version 27. Descriptive statistics were reported 
for demographic information and frequencies for all Sarcopenia-related questions. A series of 
one-way Analysis of Variance (ANOVA) tests were conducted to examine the influence of 




Chapter 4. Results 
Demographics 
 Of the 210 survey participants, 27.6% (n=58) identified between 21-30 years of age, 
27.1% (n=57) were 31-40, 16.7% (n=35) were 41-50, 13.3% (n=28) were 51-60 and 15.2% (32) 
were 60 years or older. Most of the participants (53.8%) hold a master’s degree (n=113) 
followed by 39.5% with a bachelor’s degree (n=83), 5.7% with a doctorate degree (n=12), and 
1.0% (n=2) indicating highest level of education as other. Of all respondents, 90.5% (n=190) 
were currently practicing RDNs, 5.7% (n=12) were not currently practicing, 3.3% (n=7) were 
retired, and 0.5% (n=1) declined to answer. Of the states represented in this survey, states not 
explicitly accounted for include Alaska, Delaware, Montana, Oregon, Vermont, Wisconsin, and 
Wyoming although 1.9% (n=4) identified practicing in more than one state. Of the 210 survey 
participants, 38.6% (n=81) are members of Dietetic Practice Groups (DPGs) while 58.6% 
(n=123) are not. Out of the 81 participants who are members of DPGs, 40.7% (n=33) are 
members of more than one DPG. In terms of practice settings for survey participants, 22.4% 
(n=47) work in more than one setting, 20.5% (n=43) work in inpatient acute care, 11.0% (n=23) 
work in ambulatory or outpatient facilities, 10.5% (n=22) work in settings not listed, while the 
remaining 35.6% (n=75) work in one of the other fourteen settings listed. Survey participants 





Participant Demographics (n=210) 




Age 21-30 58 27.6 
 31-40 57 27.1 
 41-50 35 16.7 
 51-60 28 13.3 
 60+ 32 15.2 
Highest earned 
degree 
Bachelor’s 83 39.5 
 Master’s 113 53.8 
 Doctorate 12 5.7 
 Other 2 1.0 
Currently 
practicing 
Yes 190 90.5 
 No 12 5.7 
 Retired 7 3.3 
 Prefer not to answer 1 0.5 
Member of DPG Yes 81 38.6 
 No 123 58.6 
 Retired 5 2.4 
 Prefer not to answer 1 0.5 
Practice setting Acute care – inpatient 43 20.5 
 Acute care – outpatient 13 6.2 
 Ambulatory/outpatient care facility 23 11.0 
 College, university or academic medical 
center 
9 4.3 
 Food or equipment manufacturer, 
distributor, or retailer 
2 1.0 
 Health/fitness facility 2 1.0 
 Home health 1 0.5 
 Long-term care 17 8.1 
 Pharmaceutical or nutrition products 
manufacturer, distributor, or retailer 
3 1.4 
 Private practice 9 4.3 
 Retail 1 0.5 
 School nutrition 1 0.5 
 Social services organization 5 2.4 
 Not currently practicing 7 3.3 
 Retired 4 1.9 
 Other 22 10.5 
 Prefer not to answer 1 0.5 
 More than one setting 47 22.4 




RQ1: Do registered dietitian nutritionists routinely screen and identify patients at risk for 
sarcopenia? 
 Survey question 2.3 corresponded to this research question and read “Do you screen for 
sarcopenia?”. There were five possible responses for this question. Of the 210 survey 
participants, 6.2% (n=13) and 22.4% (n=47) do screen for sarcopenia either per company policy 
or if indicated, respectively. Of those who do not screen for sarcopenia, 5.2% (n=11) do not 
screen for sarcopenia and stated that a colleague screens while 59.5% (n=125) never screen. In 





Survey Question 2.3 "Do You Screen for Sarcopenia?" 
 
Figure 1. Survey Question 2.3 "Do You Screen for Sarcopenia?" 
 Based on these responses, 28.6% (n=60) of RDNs who participated in this study do 
screen for sarcopenia while 64.7% (n=136) do not screen for sarcopenia. These results agree with 
the hypothesis that RDNs do not routinely screen and identify patients at risk for sarcopenia. Of 
note, survey question 2.2 asked “Are you familiar with sarcopenia?”. Respondents could select 
among yes, no, and somewhat. Of the 14 respondents who selected unsure to question 2.3, 71.4% 
(n=10) selected yes, 7.2% (n=1) selected no, and 21.4% (n=3) selected somewhat to question 
2.2. This is indicative of some level of knowledge of what sarcopenia is, but these RDNs are not 
sure what the screening or identification processes of sarcopenia entails.  
RQ2: Are there any screening tools which are commonly used to screen and identify patients at 
risk for sarcopenia, and are there any protocols in place? 
Yes, routinely per 
company policy, 13
Yes, if indicated, 47






 The first segment of this research question is addressed by survey question 2.5 and the 
latter segment by survey question 2.7. Survey question 2.5 stated “What tool(s) do you use to 
screen for sarcopenia?” and gave the option to select multiple responses as well as an open text 
for additional screening tools not listed. Survey question 2.5 was only visible to those 
participants who selected either of the yes answer choices in question 2.3. Of the 49 participants 
who answered, 8.2% (n=4) selected SARC-F, 18.4% (n=9) selected the MSRA-5 questionnaire, 
2.0% (n=1) selected the MSRA-7 questionnaire, 63.3% (n=31) selected the use of a tool not 
listed and 8.2% (n=4) selected the use of more than one tool (Figure 2). There were no selections 





Survey Question 2.5 “What Tool(s) do You Use to Screen for Sarcopenia?” 
 
Figure 2. Survey Question 2.5 “What Tool(s) do You Use to Screen for Sarcopenia?” 
 Of the 31 RDNs who used a tool other than the options listed, 51.6% (n=16) used 
nutrition focused physical exam (NFPE), 9.7% (n=3) used an unvalidated personal tool and 
38.7% (n=12) used ASPEN (American Society of Parenteral and Enteral Nutrition) guidelines or 
other validated malnutrition screening tool.  
 Addressing the latter segment of this research question, survey question 2.7 stated “Does 
your facility/practice have any sarcopenia screening protocols in place?”. Responses regarding 
sarcopenia screening protocols included 6.2% (n=13) selecting yes, 71.9% (n=151) selecting no, 
and 21.9% (n=46) selecting unsure of any protocols (Figure 3).   
 
SARC-F, 4, 8%









Survey Question 2.7 “Does Your Facility/Practice Have any Sarcopenia Screening Protocols in 
Place?” 
 
Figure 3. Survey Question 2.7 “Does Your Facility/Practice Have any Sarcopenia Screening Protocols in Place?” 
 Based on the data gathered from the survey results, the hypothesis that screening tools 
and protocols used to screen and identify patients at risk for sarcopenia are not commonly seen in 
practice is supported. 
RQ3: Is there a need and/or a desire for education for registered dietitian nutritionists on what 
sarcopenia is and how to conduct screening? 
 Survey questions 3.9 and 3.10 addressed this research question. Survey question 3.9 
polled RDNs by asking “Would you be interested in sarcopenia education?”. The majority of 
participants responded that they would be interested with 68.1% (n=143), 21.4% (n=45) would 
not be interested, and 10.5% (n=22) were unsure (Figure 4). Of the 143 participants who would 






format of sarcopenia education would you be interested in?”. Participants were given the options 
of webinars, virtual training, online modules, and CPE (Continuing Professional Education), as 
well as the options to select more than one and other. Of the 143 responses, 30.8% (n=44) 
selected all four options, 15.4% (n=22) selected three options except virtual training, 14.0% 
(n=20) selected webinars and CPE (Table 3). 
Figure 4 
Survey Question 3.9 “Would You be Interested in Sarcopenia Education?” 
 










Survey Question 3.10 “What Format of Sarcopenia Education Would You be Interested in?” 
Education Participants (n) Participants (%) 
Webinars 12 8.4 
Virtual training 3 2.1 
Online modules 2 1.4 
CPE 12 9.1 
Other 0 0.0 
All four options 44 30.8 
Webinars, online modules, CPE 22 15.4 
Virtual training, online modules, CPE 6 4.2 
Webinars, CPE 20 14.0 
Webinars, virtual training, CPE 8 5.6 
Virtual training, CPE 2 1.4 
Webinar, virtual training, online modules 3 2.1 
Online modules, CPE 3 2.1 
Webinars, virtual training 2 1.4 
Webinars, online modules 3 2.1 
Table 3. Survey Question 3.10 “What Format of Sarcopenia Education Would You be Interested in?” 
 In terms of the universal need for sarcopenia education, survey questions 2.2 and 2.3 that 
were discussed above under “Research Question 1” also contribute to this research question. 
Responses for survey questions 2.2 and 2.3 that questioned, “Are you familiar with sarcopenia?” 
and “Do you screen for sarcopenia?” respectively, indicate the need for sarcopenia education. 
Regarding survey question 2.2, 27.1% (n=57) of participants responded no or somewhat while 
72.9% (n=153) responded yes. Although this is not strictly indicative of the lack of sarcopenia 
knowledge, the 153 respondents’ level of knowledge from seeing the term in an article to 
actively practicing and researching sarcopenia can be highly variable. In contrast, need for 
sarcopenia education is supported by survey question 2.3 in which only 28.6% (n=60) do screen 
for sarcopenia while 64.7% (n=136) do not screen for sarcopenia, and 6.7% (n=14) were unsure 
if they screen for sarcopenia. Based on the responses to survey questions 3.9, 3.10, 2.2, and 2.3, 
the hypothesis that there is a need for education for RDNs on what sarcopenia is and how to 




 Survey question 2.3, which stated “Do you screen for sarcopenia?” led to a follow up 
question for participants who selected the option of “No, a colleague does”. Of the 5.2% (n=11) 
that selected this answer choice, follow up question 33 was then posed “What is the colleague's 
profession that screens for sarcopenia?”. Several healthcare professions were listed, but 
respondents were given the option to select multiple professions, select unsure, and write in a 
response. Of the 11 respondents to this question, seven selected only physician, one selected 
nurse, one selected unsure, one selected both physician and nurse, and one selected physician, 
physical therapist, and occupational therapist (Figure 5). 
Figure 5 
Survey Question 33 “What is the Colleague's Profession that Screens for Sarcopenia?” 
 

















Physician Nurse PT OT Unsure Other Physician, Nurse Physician, PT, OT
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 Survey question 2.4 questioned “If sarcopenia screening is indicated, what triggers 
determine this?” and gave participants the option to select multiple responses and write in a 
response. This survey question only became visible if a participant selected the option “Yes, if 
indicated” to survey question 2.3. Of the 48 responses to this question, 4.2% (n=2) selected 
malnutrition, 2.1% (n=1) selected physical activity, 2.1% (n=1) selected nutrition focused 
physical exam (NFPE), 2.1% (n=1) selected other, 18.8% (n=9) selected 2 triggers, 22.9% 
(n=11) selected 3 triggers, 27.1% (n=13) selected 4 triggers, 8.3% (n=4) selected 5 triggers, 
10.4% (n=5) selected 6 triggers and 2.1% (n=1) selected 7 triggers. Exact count of each trigger 
selected can be found in Table 4 and Figure 6. 
Table 4 
Survey Question 2.4 “If Sarcopenia Screening is Indicated, What Triggers Determine This?” 





Age  25 15.2 
Fall risk  8 4.9 
Malnutrition  38 23.2 
Body weight  30 18.3 
Physical activity  13 7.9 
NFPE  36 22.0 
Chronic inflammatory 
disease 
 6 3.7 
Other    
 Lean mass, fat free mass, strength 1 0.6 
 Reason for referral (malnutrition, 
request for supplements, weight 
loss, skin breakdown) 
1 0.6 
 Pediatrics 1 0.6 
 NFEP 1 0.6 
 Referral from provider 1 0.6 
 Psych medications 1 0.6 
 Nutrition lab values 1 0.6 
 MST 1 0.6 




Survey Question 2.4 “If Sarcopenia Screening is Indicated, What Triggers Determine This?” 
 
Figure 6. Survey Question 2.4 “If Sarcopenia Screening is Indicated, What Triggers Determine This?” 
In response to RQ2, survey question 2.7 defined above found that 6.2% (n=13) 
respondents’ workplace has sarcopenia screening protocols in place. Although not statistically 
significant, survey question 2.7 was correlated with survey question 1.10 which questioned “In 
what setting(s) do you commonly practice?”. Of the 13 participants who selected yes to question 
2.7, 30.7% (n=4) practice in more than one setting, 15.4% (n=2) practice in the acute care 
inpatient setting, 15.4% (n=2) practice in the acute care outpatient setting, 15.4% (n=2) work in a 
college, university or academic medical center, 7.7% (n=1) work in an ambulatory/outpatient 
care facility, 7.7% (n=1) practice in a long-term care facility, and 7.7% (n=1) work in private 















Survey Question 1.10 “In What Setting(s) Do You Commonly Practice?” 
 
Figure 7. Survey Question 1.10 “In What Setting(s) Do You Commonly Practice?” 
  



















Chapter 5. Conclusion 
 As expected, all hypotheses of the three proposed research questions were proven and 
null hypotheses were voided. This research in whole and in parts have both reiterated and shed 
light on other aspects regarding sarcopenia knowledge, protocols, and education needs by a 
sample of RDNs in the U.S. The lack of standardized screening, assessment and treatment 
protocols in place are apparent. Subsequently, there is an overlook for a population of individuals 
who could potentially benefit greatly from sarcopenia treatment interventions. 
Limitations 
 This study had several limitations. First, the study sample of 210 RDNs cannot be 
generalized to the RDN population as a whole. Secondly, this research extended only to 
registered dietitian nutritionists and does not include the plethora of other healthcare 
professionals. By extension, the study sample size cannot be generalized to all healthcare 
professionals as whole.  
Future Research 
 Initial study methods were to include physical assessments of community-dwelling older 
adults. However, due to COVID-19 protocols, it was not possible to visit this population. Future 
research possibilities could include collecting data regarding physical and nutrition assessments 
of community-dwelling older adults. Through this research, more information could be gathered 
regarding screening and assessment protocols already in place as well as shortcomings in this 
area.  
 In addition, further investigations into organizations throughout the U.S. and the world to 
define protocols that are both in place and lacking regarding sarcopenia could be of value. 
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Findings of this research could assist in detecting larger-spectrum shortcomings rather than just 
individuals in practice. 
 Once a definition and screening criteria has been globally agreed upon, next steps into 
treatment of sarcopenia would be necessary. Similar to the processes of how screening and 
diagnostic tools have been studied, more extensive research would be essential in order to 
properly treat this debilitating disease. 
 Next steps regarding this sarcopenia research would initially include education to RDNs 
and other healthcare professionals as well as voicing the importance of this disease and call for 
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Appendix A. SARC-F Screen for Sarcopenia 
SARC-F Screen for Sarcopenia 
Component Question Scoring 
Strength How much difficulty do you have in 
lifting and carrying 10 pounds? 
None = 0 
Some = 1 
A lot or unable = 2 
Assistance in walking How much difficulty do you have 
walking across a room? 
None = 0 
Some = 1 
A lot, use aids, or 
unable = 2 
Rise from a chair How much difficulty do you have 
transferring from a chair or bed? 
None = 0 
Some = 1 
A lot or unable 
without help = 2 
Climb stairs How much difficulty do you have 
climbing a flight of 10 stairs? 
None = 0 
Some = 1 
A lot or unable = 2 
Falls How many times have you fallen in the 
past year? 
None = 0 
1-3 falls = 1 
4 or more falls = 2 





Appendix B. Formula for Ishii’s Score 
Formula for Ishii’s Score 
The exact formula to calculate the scores are as follows:  
Score in men, 0.62 × (age – 64) – 3.09 × (grip strength – 50) –4.64 × (calf circumference – 42) 
Score in women, 0.80 × (age – 64) – 5.09 × (grip strength – 34) – 3.28 × (calf circumference – 
42).  
 
The corresponding probabilities of sarcopenia are calculated with the following formulae: 
Probability in men, 1 / [1 + e−(sum score / 10–11.9)]  
Probability in women, 1 / [1 + e−(sum score / 10–12.5)] 
 
Note: Reused with permission through John Wiley and Sons and Copyright Clearance Center. 




Appendix C. The Mini Sarcopenia Risk Assessment (MSRA) 7 and 5 items Questionnaire 
The Mini Sarcopenia Risk Assessment (MSRA) 7 and 5 items Questionnaire 
 7 items 5 items 









2-Were you hospitalized in the last year? 
Yes, and more than one hospitalization 










3-What is your activity level? 
I’m able to walk less than 1000 meters 







4-Do you eat 3 meals per day regularly? 
No, up to twice per week I skip a meal (for example I 













5-Do you consume any of the following? 
Milk or dairy products (yogurt, cheese), but not every 
day 










6-Do you consume any of the following? 
Poultry, meat, fish, eggs, legumes, ragout or ham, but 
not every day 
Poultry, meat, fish, eggs, legumes, ragout or ham at least 























Appendix D. Sarcopenia Quality of Life (SarQoL) Survey – Validated English Translation 

















Note: Reused with written permission from Olivier Bruyere, creator of the original SarQoL in 
French. All published translations can also be found at www.sarqol.org.   
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Appendix E. Sarcopenia Survey 
Sarcopenia Survey 
 
Start of Block: Demographics 
Q1.1 Demographics Questions 
 
Q1.2 Age: 
o 21-30  
o 31-40  
o 41-50  
o 51-60  
o 60+  




Q1.3 Years in practice: 
o Less than 1  
o 1-5  
o 6-10  
o 11-15  
o 16-20  
o 20+  
o Prefer not to answer  
 
 
Q1.4 What is your highest level of education? 
o Bachelor's Degree  
o Master's Degree  
o Doctorate Degree  
o Other  
o Prefer not to answer  
 
 






Q1.6 Are you currently practicing? 
o Yes  
o No  
o Retired  
o Prefer not to answer  
 
 
Display This Question: 




Q1.7 If yes, in what state(s) do you currently practice? 
▢ AK  
▢ AL  
▢ AR  
▢ AZ  
▢ CA  
▢ CO  
▢ CT  
▢ DE  
▢ FL  
▢ GA  
▢ HI  
▢ IA  
▢ ID  
▢ IL  
▢ IN  
▢ KS  
▢ KY  
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▢ LA  
▢ MA  
▢ MD  
▢ ME  
▢ MI  
▢ MN  
▢ MO  
▢ MS  
▢ MT  
▢ NC  
▢ ND  
▢ NE  
▢ NH  
▢ NJ  
▢ NM  
▢ NV  
▢ NY  
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▢ OH  
▢ OK  
▢ OR  
▢ PA  
▢ RI  
▢ SC  
▢ SD  
▢ TN  
▢ TX  
▢ UT  
▢ VA  
▢ VT  
▢ WA  
▢ WI  
▢ WV  
▢ WY  




Q1.8 Are you a member of any Dietetic Practice Groups (DPGs)? 
o Yes  
o No  
o Retired  




Display This Question: 
If Q1.8 = Yes 
 
Q1.9 Which DPGs are you a member of? Please select all that apply. 
▢ Behavioral Health Nutrition  
▢ Clinical Nutrition Management  
▢ Diabetes  
▢ Dietetics in Health Care Communities  
▢ Dietitians in Business and Communications  
▢ Dietitians in Integrative and Functional Medicine  
▢ Dietitians in Nutrition Support  
▢ Food and Culinary Professionals  
▢ Healthy Aging  
▢ Hunger and Environmental Nutrition  
▢ Management in Food and Nutrition Systems  
▢ Medical Nutrition Practice Group  
▢ Nutrition Education for the Public  
▢ Nutrition Educators of Health Professionals  
▢ Nutrition Entrepreneurs  
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▢ Nutrition Informatics  
▢ Oncology Nutrition  
▢ Pediatric Nutrition  
▢ Public Health/Community Nutrition  
▢ Renal Dietitians  
▢ Research  
▢ School Nutrition Services  
▢ Sports Cardiovascular and Wellness Nutrition  
▢ Vegetarian Nutrition  
▢ Weight Management  
▢ Women's Health  




Q1.10 In what setting(s) do you commonly practice? 
▢ Acute Care - Inpatient  
▢ Acute Care - Outpatient  
▢ Ambulatory/Outpatient Care Facility  
▢ College, University or Academic Medical Center  
▢ Food or Equipment Manufacturer, Distributor, or Retailer  
▢ Health/Fitness Facility  
▢ Home Health  
▢ Long-Term Care  
▢ Pharmaceutical or Nutrition Products Manufacturer, Distributor, or Retailer  
▢ Private Practice  
▢ Retail  
▢ School Nutrition  
▢ Social Services Organization  
▢ Not Currently Practicing  
▢ Retired  
▢ Other, please specify: ________________________________________________ 




End of Block: Demographics 
 
Start of Block: Part 1 
Q2.1 Part 1 
 Sarcopenia is historically defined as “the age-related loss of skeletal muscle mass and/or 
muscle function”.  
 
Q2.2 Are you familiar with sarcopenia? 
o Yes  
o No  
o Somewhat  
 
Q2.3 Do you screen for sarcopenia? 
▢ Yes, routinely per company policy  
▢ Yes, if indicated  
▢ No, a colleague does  
▢ No, never  




Display This Question: 
If Q2.3 = No, a colleague does 
Q33 What is the colleague's profession that screen for sarcopenia? Please select all that apply. 
▢ Physician  
▢ Nurse  
▢ Physical Therapist  
▢ Occupational Therapist  
▢ Unsure  




Display This Question: 
If Q2.3 = Yes, if indicated 
Q2.4 If sarcopenia screening is indicated, what triggers determine this? Please select all that 
apply. 
▢ Age  
▢ Fall Risk  
▢ Malnutrition  
▢ Body Weight  
▢ Physical Activity  
▢ Nutrition Focused Physical Exam  
▢ Chronic Inflammatory Disease  




Display This Question: 
If Q2.3 = Yes, routinely per company policy 
Or Q2.3 = Yes, if indicated 
Q2.5 What tool(s) do you use to screen for sarcopenia? Please select all that apply. 
▢ SARC-F (Strength, Assistance in walking, Rise from a chair, Climb stairs, Falls)  
▢ Ishii’s Score  
▢ MSRA-5 (Mini Sarcopenia Risk Assessment 5-question)  
▢ MSRA-7 (Mini Sarcopenia Risk Assessment 7-question)  
▢ Other, please specify: ________________________________________________ 
 
Q2.6 Are you familiar with any of the sarcopenia screening tools listed below? Please select all 
that apply. 
o SARC-F (Strength, Assistance in walking, Rise from a chair, Climb stairs, Falls)  
o Ishii’s Score  
o MSRA-5 (Mini Sarcopenia Risk Assessment 5-question)  
o MSRA-7 (Mini Sarcopenia Risk Assessment 7-question)  
o Other, please specify: ________________________________________________ 




Q2.7 Does your facility/practice have any sarcopenia screening protocols in place? 
o Yes  
o No  
o Unsure  
 
Q2.8 Does your facility/practice have follow-up protocols for those diagnosed with sarcopenia? 
o Yes  
o No  
o Unsure  
 
Q2.9 Do you utilize handgrip strength measurements?  
o Yes  
o No  
 
Display This Question: 
If Q2.9 = Yes 
Q2.10 In what ways do you utilize handgrip strength? Please select all that apply. 
▢ Muscle Strength  
▢ Malnutrition  
▢ Frailty  




Q2.11 Do you refer to other healthcare professions for sarcopenia screening/diagnosis/treatment, 
or do other professions refer to RDNs in your facility? Please select all that apply. 
▢ Yes, I refer to colleague(s)  
▢ Yes, colleague(s) refer to me  
▢ No, I do not refer out or receive referrals regarding sarcopenia  
▢ Unsure  
 
Display This Question: 
If Q2.11 = Yes, I refer to colleague(s) 
Or Q2.11 = Yes, colleague(s) refer to me 
Q34 What is the profession of the colleague(s) which you refer to or who refer to you? Please 
select all that apply. 
▢ Physician  
▢ Nurse  
▢ Physical Therapist  
▢ Occupational Therapist  
▢ Unsure  
▢ Other, please specify: ________________________________________________ 
End of Block: Part 1 
 
Start of Block: Part 2 
 
Q3.1 Part 2 Sarcopenia was defined in 2018 by the European Working Group on Sarcopenia in 
Older People (EWGSOP2) as “a muscle disease (muscle failure) rooted in adverse muscle 
changes that accrue across a lifetime; sarcopenia is common among adults of older age but can 
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also occur earlier in life”. This proposes that sarcopenia is not only age-related but can be a 
pathology as well.  Inclusion criteria set forth by EWGSOP2 are comprised of low muscle 
strength, low muscle quality or quantity, low physical performance. 
 
Q3.2 Were you previously aware of this proposed definition? 
o Yes  
o No  
 
Q3.3 Does this proposed definition affect the way you see sarcopenia? 
o Yes  
o No  
o Unsure  
 
Display This Question: 
If Q3.3 = Yes 
Q3.4 In what ways does this proposed definition affect the way you see sarcopenia? Please select 
all that apply. 
▢ In practice  
▢ In research  




Q3.5 Do you feel this proposed definition requires any modification? 
o Yes  
o No  
o Unsure  
 
Display This Question: 
If Q3.5 = Yes 
Q3.6 In what ways do you feel this proposed definition needs modification? 
▢ "Muscle disease" should be omitted  
▢ Inclusion criteria  
▢ Younger age inclusion  
▢ Other, please specify: ________________________________________________ 
 
Q3.7 Does this proposed definition affect the way we will respond to sarcopenia as RDNs? 
o Yes  
o No  
o Unsure  
 
Q3.9 Would you be interested in sarcopenia education?  
o Yes  
o No  




Display This Question: 
If Q3.9 = Yes 
Q3.10 What format of sarcopenia education would you be interested in? Please select all that 
apply. 
▢ Webinars  
▢ Virtual Training  
▢ Online Modules  
▢ Continuing Professional Education (CPE)  
▢ Other, please specify: ________________________________________________ 
 
 
Q32 Please include any additional comments or suggestions below: 
________________________________________________________________ 















6 levels (SARC-F (Strength, Assistance in walking, Rise from a chair, 
Climb stairs, Falls); Ishii’s Score; MSRA-5 (Mini Sarcopenia Risk 
Assessment 5-question); MSRA-7 (Mini Sarcopenia Risk Assessment 7-












15 levels (Webinars; Virtual Training; Online Modules; Continuing 
Professional Education (CPE); Other; All 4 options; Webinars, Online 
Modules, CPE; Virtual Training, Online Modules, CPE; Webinars, CPE; 
Webinars, Virtual Training, CPE; Virtual Training, CPE; Webinar, Virtual 
Training, Online Modules; Online Modules, CPE; Webinars, Virtual 
Training; Webinars, Online Modules) 
Age 6 levels (21-30; 31-40; 41-50; 51-60; 60+; Prefer not to answer) 
Years in Practice 7 levels (Less than 1; 1-5; 6-10; 11-15; 16-20; 20+; Prefer not to answer) 
States of Practice 54 levels (50 U.S states individually; Prefer not to answer; Other; More than 
one state; Retired/not currently practicing) 
Highest Level of 
Education 
5 levels (Bachelor’s degree; Master’s degree; Doctorate degree; Other; 
Prefer not to answer) 
Currently 
Practicing RDN 
4 levels (Yes; No; Retired; Prefer not to answer) 
Practice Settings 18 levels (Acute Care – Inpatient; Acute Care – Outpatient; 
Ambulatory/Outpatient Care Facility; College, University or Academic 
Medical Center; Food or Equipment Manufacturer, Distributor, or Retailer; 
Health/Fitness Facility; Home Health; Long-Term Care; Pharmaceutical or 
Nutrition Products, Manufacturer, Distributor, or Retailer; Private Practice; 
Retail; School Nutrition; Social Services Organization; Not Currently 
Practicing; Retired; Other; Prefer not to answer; More than one setting) 
Familiar with 
Sarcopenia 





8 levels (Physician; Nurse; Physical Therapist; Occupational Therapist; 






14 levels (Age; Fall risk; Malnutrition; Body weight; Physical activity; 
Nutrition Focused Physical Exam; Chronic inflammatory disease; Other; 2 
triggers selected; 3 triggers selected; 4 triggers selected; 5 triggers selected; 
6 triggers selected; 7 triggers selected) 
RDNs Refer for 
Sarcopenia 
Screening 
4 levels (Yes, I refer to colleague(s); Yes, colleague(s) refer to me; No, I do 





2 levels (Yes; No) 
Member of DPG 
group(s) 
28 levels (Behavioral Health Nutrition; Clinical Nutrition Management; 
Diabetes; Dietetics in Health Care Communities; Dietitians in Business and 
Communications; Dietitians in Integrative and Functional Medicine; 
Dietitians in Nutrition Support; Food and Culinary Professionals; Healthy 
Aging; Hunger and Environmental Nutrition; Management in Food and 
Nutrition Systems; Medical Nutrition Practice Group; Nutrition Education 
for the Public; Nutrition Educators of Health Professionals; Nutrition 
Entrepreneurs; Nutrition Informatics; Oncology Nutrition; Pediatric 
Nutrition; Public Health/Community Nutrition; Renal Dietitians; Research; 
School Nutrition Services; Sports Cardiovascular and Wellness Nutrition; 
Vegetarian Nutrition; Weight Management; Women's Health; Prefer not to 
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